Borderline products

Although it may be immediately obvious that a product is a medicine and should be regulated as such, some products are more difficult to distinguish from medicines or medical devices and may function for a medicinal purpose and another purpose, such as a cosmetic purpose. For these products, the classification is not immediately clear and multiple regulatory frameworks may apply. For example, it may be uncertain whether a more complex healthcare product might be viewed as a medical device, cosmetic, food, dietary supplement, herbal medicine or biocidal product. Sometimes it is certain circumstances or if certain criteria are met or even claims made about the product’s use that might cause it to be classified as a medicinal product, so it can be unclear which regulatory framework one should comply with for an effective regulatory strategy. These products are called borderline products until their status has been decided.

The regulatory classification of a product can have important ramifications, for example, on how the product is regulated (and by whom), how long it will take before such product can be commercialised (especially if pre-market approval is required), how the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

MHRA publishes blog post highlighting £1.4bn opportunity from medicines reclassification

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a blog post authored by Proprietary Association of Great Britain (PAGB) CEO, Michelle Riddalls OBE, outlining what PAGB describes as a £1.4bn opportunity to transform healthcare through expanded medicines reclassification. Riddalls argues that increasing switches from prescription-only (POM) to pharmacy (P) or general sales list (GSL) status could improve timely access to treatments for common conditions, strengthen self-care and ease pressure on primary care, with the MHRA describing reclassification as a practical way to broaden access to trusted medicines and enable safe self-management of minor conditions. She states that 74% of adults want more medicines available without a prescription, positioning consumer demand as a key driver of switch applications, and frames reclassification as a catalyst for a prevention-focused healthcare model that enhances the role of community pharmacists and supports wider public health goals. Referencing previous switches to over-the-counter (OTC) status, including Nurofen, Allevia and Calpol, as well as low-dose vaginal oestrogen products and Viagra, she highlights both market impact and social significance and calls for reform of the legal framework for certain injectable medicines, pointing to potential benefits in areas including weight management and emergency treatments. Riddalls states that a 5% reduction in NHS prescribing could save £1.4bn annually, with productivity gains of up to £18bn linked to improved OTC symptom management. PAGB adds that reclassification is one of the most practical and impactful opportunities to strengthen self-care and deliver the ambitions of the NHS 10 Year Plan, citing clear opportunity, strong public demand and persuasive supporting evidence.

View Life Sciences by content type :

Popular documents